Start038290 • KOSDAQ
add
Macrogen Inc
Seneste lukkekurs
16.150,00 ₩
Dagsinterval
16.210,00 ₩ - 16.650,00 ₩
Årsinterval
14.920,00 ₩ - 26.700,00 ₩
Markedsværdi
177,01 mia. KRW
Gns. volumen
62,86 t
P/E-værdi
-
Udbytteprocent
1,82 %
Primær børs
KOSDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (KRW) | sep. 2024info | År til år-ændring |
|---|---|---|
Indtægt | 33,00 mia. | 2,20 % |
Driftsudgifter | 13,80 mia. | 4,68 % |
Nettoindtægt | -3,18 mia. | -60,92 % |
Overskudsgrad | -9,64 | -57,52 % |
Earnings per share | — | — |
EBITDA | 2,21 mia. | 47,21 % |
Effektiv afgiftssats | 1,20 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (KRW) | sep. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 24,60 mia. | 8,61 % |
Samlede aktiver | 274,19 mia. | 3,79 % |
Samlede passiver | 124,82 mia. | 40,99 % |
Samlet egenkapital | 149,37 mia. | — |
Shares outstanding | 9,97 mio. | — |
Kurs/indre værdi | 1,09 | — |
Afkast af aktiver | -0,54 % | — |
Afkast af kapital | -0,70 % | — |
Pengestrøm
Nettoændring i likviditet
| (KRW) | sep. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | -3,18 mia. | -60,92 % |
Pengestrøm fra drift | -2,08 mia. | 50,99 % |
Pengestrøm fra investering | -9,57 mia. | -22,48 % |
Pengestrøm fra finansiering | 6,73 mia. | 594,06 % |
Nettoændring i likviditet | -4,51 mia. | 58,99 % |
Fri pengestrøm | -10,07 mia. | 35,34 % |
Om
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Administrerende direktør
Grundlagt
5. jun. 1997
Website
Ansatte
519
